Authors: Lippman, SM Lee, JJ Karp, DD Vokes, EE Benner, SE Goodman, GE Khuri, FR Marks, R Winn, RJ Fry, W Graziano, SL Gandara, DR Okawara, G Woodhouse, CL Williams, B Perez, C Kim, HW Lotan, R Roth, JA Hong, WK

Citation: Sm. Lippman et al., Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer, J NAT CANC, 93(8), 2001, pp. 605-618

Authors: Graziano, SL Tatum, A Herndon, JE Box, J Memoli, V Greene, MR Kern, JA

Citation: Sl. Graziano et al., Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study, LUNG CANC, 33(2-3), 2001, pp. 115-123

Authors: Gajra, A Mehdi, SA Kirshner, J Newman, N Graziano, SL

Citation: A. Gajra et al., Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma, LUNG CANC, 32(2), 2001, pp. 189-196

Authors: Mathur, SC Friedman, HD Kende, AI Davis, RL Graziano, SL

Citation: Sc. Mathur et al., Cryptic Mucor infection leading to massive cerebral infarction at initiation of antileukemic chemotherapy, ANN HEMATOL, 78(5), 1999, pp. 241-245

Authors: Graziano, SL Gamble, GP Newman, NB Abbott, LZ Rooney, M Mookherjee, S Lamb, ML Kohman, LJ Poiesz, BJ

Citation: Sl. Graziano et al., Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer, J CL ONCOL, 17(2), 1999, pp. 668-675